About Viatris
Viatris is a company based in Frankfurt (Germany) founded in 1998 was acquired by Insud Pharma in March 2024. The company has 32,000 employees as of December 31, 2024. Viatris has completed 3 acquisitions, including Aculys, Famy Life Sciences and Oyster Point Pharmaceuticals. Viatris offers products and services including Generic Medicines and Branded Products.
- Headquarter Frankfurt, Germany
- Employees 32000 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Viatris Inc.
-
Annual Revenue
$14.71 B (USD)-4.37as on Dec 31, 2024
-
Net Profit
-$634.2 M (USD)-1259.41as on Dec 31, 2024
-
EBITDA
$4.57 B (USD)-3.44as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Insud Pharma
& 1 more
-
Employee Count
32000
as on Dec 31, 2024
-
Investments & Acquisitions
Aculys
& 2 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Viatris
Viatris is a publicly listed company on the NASDAQ with ticker symbol VTRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Viatris
Viatris offers a comprehensive portfolio of products and services, including Generic Medicines and Branded Products.
Generic drugs are developed and distributed by Viatris across therapeutic areas to address noncommunicable and infectious diseases.
Branded generics and other medicines are offered by Viatris to enhance access in global markets.
People of Viatris
Unlock access to complete
Unlock access to complete
Software Development Team
176 people
Leadership Team
83 people
Senior Team
55 people
Sales and Marketing
54 people
Head Team
44 people
Product Management Team
36 people
Finance and Accounting
28 people
Human Resources and Administration
27 people
Unlock access to complete
Funding Insights of Viatris
Detailed funding history for Viatris
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Viatris
Viatris has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Insud Pharma and Mylan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finished formulations, APIs, and monoclonal antibodies are developed and manufactured.
|
Locked | Locked | Locked | |
|
Mylan, part of Viatris, is focused on healthcare solutions.
|
Locked | Locked | Locked |
Investor details for Viatris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Viatris
Viatris has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Aculys, Famy Life Sciences and Oyster Point Pharmaceuticals.
Investment portfolio details for Viatris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutic medicines for neuropsychiatric and sleep disorders are developed.
|
Locked | Locked | 2021 | Locked | |
|
Gene therapies for ophthalmological diseases are developed.
|
Locked | Locked | 2015 | Locked | |
|
Drug development services are offered for ophthalmology, oncology, and dermatology.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Viatris
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Viatris
Detailed financials for Viatris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viatris Comparisons
Peer comparison for Viatris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Viatris
Detailed competitors of Viatris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viatris
Complete news archive for Viatris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viatris
Viatris was founded in 1998.
Viatris is headquartered in Frankfurt, Germany. It is registered at Frankfurt, Hesse, Germany.
Scott A Smith is the current CEO of Viatris.
As of Dec 31, 2024, the latest employee count at Viatris is 32,000.
Annual revenue of Viatris is $14.71B as on Dec 31, 2024.
Viatris was established in 1998 and is headquartered in Frankfurt, Germany, within the pharmaceuticals sector. Branded drugs are developed and marketed globally by the company, focusing on therapeutic solutions. Operations span research, manufacturing, and distribution across multiple regions. In 2022, annual revenues of 16.26 billion were achieved, alongside a net profit of 2.07 billion. Leadership is provided by CEO Scott A. Smith.
Viatris offers Generic Medicines and Branded Products.
Yes, Viatris is publicly traded on NASDAQ under the ticker symbol VTRS.
Viatris has made 3 acquisitions, including Aculys, Famy Life Sciences, and Oyster Point Pharmaceuticals.
Viatris has 2 investors. Key investors include Insud Pharma, and Mylan.
The ticker symbol of Viatris is VTRS on NASDAQ.